All Pharma News
Seagen’s former commercial chief joins the board at healthcare agency

Seagen’s former commercial chief joins the board at healthcare agency
Beth Snyder Bulik ENDPTS
22 Mar 2024
Share Share
Seagen patent invalidated in long-running Daiichi Sankyo spat

Seagen patent invalidated in long-running Daiichi Sankyo spat
FIERCE PHARMA
18 Jan 2024
Share Share
Patent Office Invalidates Seagen Patent in Dispute between Daiichi and Seagen

Patent Office Invalidates Seagen Patent in Dispute between Daiichi and Seagen
BUSINESSWIRE
16 Jan 2024
Share Share
Pfizer`s $43B buyout of ADC specialist Seagen is a done deal

Pfizer`s $43B buyout of ADC specialist Seagen is a done deal
Kevin Dunleavy FIERCE PHARMA
14 Dec 2023
Share Share
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights

Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
REUTERS
13 Dec 2023
Share Share
ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
BUSINESSWIRE
10 Dec 2023
Share Share
TUKYSA® Improves Progression-Free Survival in Patients with Breast Cancer

TUKYSA® Improves Progression-Free Survival in Patients with Breast Cancer
BUSINESSWIRE
06 Dec 2023
Share Share
Overall survival data blur Seagen`s Tukysa-ADC path

Overall survival data blur Seagen`s Tukysa-ADC path
Angus Liu FIERCE PHARMA
06 Dec 2023
Share Share
Seagen Highlights First Solid Tumor Data for an ADCETRIS

Seagen Highlights First Solid Tumor Data for an ADCETRIS
BUSINESSWIRE
03 Nov 2023
Share Share
Data for ADCETRIS with Combination in Hodgkin Lymphoma to be Featured

Data for ADCETRIS with Combination in Hodgkin Lymphoma to be Featured
BUSINESSWIRE
02 Nov 2023
Share Share